Trial Profile
An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin's Disease Previously Treated in Protocol MDX060-03
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Iratumumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Medarex
- 31 Aug 2019 Status changed from recruiting to completed.
- 27 Jan 2006 New trial record.